Comparative Pharmacology
Head-to-head clinical analysis: CECLOR CD versus DURICEF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CECLOR CD versus DURICEF.
CECLOR CD vs DURICEF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefaclor, a second-generation cephalosporin, inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby disrupting peptidoglycan cross-linking.
Cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
250-500 mg orally every 8 hours; extended-release form (CECLOR CD) 375-750 mg orally every 12 hours.
500 mg to 1 g orally once or twice daily.
None Documented
None Documented
Terminal elimination half-life: ~0.6-0.9 hours (prolonged in renal impairment)
1.5-2 hours (prolonged to 20-30 hours in severe renal impairment; dosing adjustment required for CrCl <50 mL/min).
Renal: ~80% unchanged; biliary/fecal: ~20%
Primarily renal (80-90% unchanged via glomerular filtration and tubular secretion); <10% biliary/fecal.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic